INmune Bio Co-Founder and CEO Presents at Maxim Group’s Conference on Alzheimer’s Disease
July 03 2019 - 9:01AM
INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused
on developing treatments that harness the patient’s innate immune
system to fight disease, announced that R.J. Tesi, M.D., the
company’s co-founder and CEO, presented at the Maxim Group’s
conference on Alzheimer’s disease on June 26 in New York. During
his presentation, Dr. Tesi addressed how INmune Bio’s drug
candidate XPro1595 targets microglial activation and
neuroinflammation to treat Alzheimer’s, which may be a key driver
in the disease.
During the conference, titled “Alzheimer's Disease – What's
Next? Treating Alzheimer's in a Post-Amyloid World,” Dr. Tesi
discussed INmune Bio’s novel approach to treating Alzheimer’s with
XPro1595, a second generation selective inhibitor of soluble TNF
(tumor necrosis factor) to combat neuroinflammation and microglial
activation. The novel biomarker-directed clinical trial design uses
inflammatory biomarkers to select patients and determine treatment
effects.
“I was delighted to showcase INmune Bio’s development program
with XPro1595 in Alzheimer’s disease,” said Dr. Tesi. “We believe
that our Phase I clinical trial supported by the Alzheimer’s
Association Part-the-Cloud Award is a positive step in exploring if
reversing microglial activation and neuroinflammation will have an
impact on this devastating disease.”
INmune Bio will begin enrolling patients into Xpro1595’s Phase I
clinical trial in the coming weeks.
About INmune Bio, Inc.INmune Bio, Inc. is a
publicly traded (NASDAQ: INMB) clinical-stage biotechnology company
developing therapies targeting the innate immune system to fight
disease. INmune Bio is developing three product platforms: two
products that reengineer the patient’s innate immune system’s
response to cancer and one product to treat neuroinflammation that
is currently focused on Alzheimer’s disease. INKmune is a natural
killer (NK) cell therapeutic that primes the patient’s NK cells to
attack minimal residual disease, the remaining cancer cells that
are difficult to detect, which often cause relapse. INB03 inhibits
myeloid-derived suppressor cells (MDSC), which often cause
resistance to immunotherapy, such as anti-PD-1 checkpoint
inhibitors. XPro1595 targets neuroinflammation, which causes
microglial activation and neuronal cell death. INmune Bio’s product
platforms utilize a precision medicine approach for the treatment
of a wide variety of hematologic malignancies, solid tumors and
chronic inflammation. To learn more, please visit
www.inmunebio.com.
INmune Bio Contact: David Moss, CFO(858)
964-3720DMoss@INmuneBio.com
Media Contact: Antenna GroupHolly
Dugan(201) 465-8019INmuneBio@AntennaGroup.com
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
From Jul 2024 to Aug 2024
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
From Aug 2023 to Aug 2024